
==== Front
NPJ Parkinsons Dis
NPJ Parkinsons Dis
NPJ Parkinson's Disease
2373-8057
Nature Publishing Group UK London

39256393
786
10.1038/s41531-024-00786-z
Article
The value of PET/CT in the diagnosis and differential diagnosis of Parkinson’s disease: a dual-tracer study
http://orcid.org/0009-0007-7035-302X
Du Xiaoxiao 1
http://orcid.org/0000-0002-9455-3743
Zhao Hongguang 2
http://orcid.org/0000-0003-3247-051X
Li Yinghua 2
Dai Yuyin 2
http://orcid.org/0000-0001-8895-5036
Gao Lulu 1
http://orcid.org/0009-0002-0556-0536
Li Yi 1
http://orcid.org/0009-0006-5610-9322
Fan Kangli 1
http://orcid.org/0009-0009-0370-4314
Sun Zhihui 1
http://orcid.org/0000-0002-4448-2051
Zhang Ying zhang_ying99@jlu.edu.cn

1
1 https://ror.org/034haf133 grid.430605.4 0000 0004 1758 4110 Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, Jilin China
2 https://ror.org/034haf133 grid.430605.4 0000 0004 1758 4110 Nuclear Medicine Department, The First Hospital of Jilin University, Changchun, Jilin China
10 9 2024
10 9 2024
2024
10 17115 1 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Positron emission tomography/computed tomography (PET/CT) is a molecular imaging method commonly used to diagnose and differentiate Parkinson’s disease (PD). This study aimed to evaluate the performance of PET/CT with 11C-2β-Carbomethoxy-3β-(4-fluorophenyl) tropane (11C-CFT) and 18F-fluorodeoxyglucose (18F-FDG) tracers in the differential diagnosis between PD, multiple system atrophy parkinsonian type (MSA-P), progressive supranuclear palsy (PSP) and vascular parkinsonism (VP) using the data of 220 patients with clinical PD-like symptoms. Of the 220 enrolled patients, 166 (PD, n = 80; MSA-P, n = 54; PSP, n = 15; VP, n = 17) completed the motor, cognitive and PET/CT assessment and were included in this study. 11C-CFT and 18F-FDG PET/CT images were analyzed using the SNBPI toolbox and CortexID Suite software. The uptake values of 11C-CFT and 18F-FDG PET/CT were compared among the groups after controlling for covariates using generalized linear models. Receiver operating characteristic (ROC) curves were generated to estimate the diagnostic values. Patients with PSP showed the most significant reduction on 11C-CFT PET/CT, while patients with PD and MSA-P showed similar reductions, and patients with VP did not show any significant reduction in 11C-CFT uptake. The areas under the curve (AUCs) for 11C-CFT PET/CT for distinguishing PD from VP, PSP, and MSA-P were 0.902, 0.830, and 0.580, respectively, and 0.728 for distinguishing advanced-stage PD from PSP. On 18F-FDG PET/CT, the AUCs for distinguishing PD from PSP and MSA-P were 0.968 and 0.963, respectively. These results suggest that 11C-CFT and 18F-FDG PET/CT complement each other in improving the accuracy in differential diagnosis of PD.

Subject terms

Parkinson's disease
Parkinson's disease
https://doi.org/10.13039/100007847 Natural Science Foundation of Jilin Province (Natural Science Foundation of Jilin Province of China) YDZJ202201ZYTS116 Zhang Ying https://doi.org/10.13039/501100009991 Department of Finance of Jilin Province (Jilin Provincial Department of Finance) JLSWSRCZX2020-0011 Zhang Ying https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 81974194 Zhang Ying Jilin Province Health and Technology Innovation Project (NO.2018J045)issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The early and accurate diagnosis of Parkinson’s disease (PD) remains challenging because of the lack of any definitive diagnostic biomarker1. Currently, the diagnosis of PD is primarily performed clinically2,3, which has a misdiagnosis rate of 20%4. Approximately 80% of the initially misdiagnosed patients are later diagnosed with multiple system atrophy parkinsonian type (MSA-P) or progressive supranuclear palsy (PSP)1,5. According to the 2015 diagnostic criteria of the International Parkinson and Movement Disorder Society (MDS), normal presynaptic dopamine activity is an exclusionary factor for PD6. 11C-2β-Carbomethoxy-3β-(4-fluorophenyl) tropane (11C-CFT) positron emission tomography/computed tomography (PET/CT) can be used to test this activity7. 11C-CFT is a radioactive tracer that selectively binds to axonal terminals in the striatum8. The level of binding reflects the degree of damage to the dopaminergic neurons in the nigrostriatal system9. Abnormal dopamine function can also help distinguish PD from essential tremor (ET) and vascular parkinsonism (VP)10, but has a limited ability to distinguish PD from MSA-P and PSP11,12, which also present as pathological lesions in the nigrostriatal system.

Neurodegenerative diseases manifest with various degrees of metabolic abnormality, which 18F-fluorodeoxyglucose (18F-FDG) PET/CT can identify at a systemic level13. Both autopsy and 18F-FDG PET/CT studies have indicated that the disease-specific glucose metabolism pattern in the brain can aid in the differential diagnosis of PD and related diseases14,15. PD typically shows hypometabolism in the posterior parietal and frontal cortices, as well as hypermetabolism in the pallidothalamic tracts and cerebellum16. However, the sample sizes of prior autopsy studies have been small. Research data from large, real-world cohorts are required to examine the potential values of these imaging methods for the differential diagnosis of PD-like disorders.

In this study, we performed 11C-CFT and 18F-FDG PET/CT scans in 166 patients with PD-like symptoms to evaluate their performance in the differential diagnosis of PD from MSA-P, PSP, and VP.

Results

Demographic and clinical data

Overall, we observed significant differences between the groups with respect to age (P = 0.006), disease duration (P = 0.005), H-Y (P < 0.001), MDS-UPDRS-III (P < 0.001), and MoCA (P = 0.004). In post-hoc analysis, VP patients were found to be older than MSA-P patients, PD patients had a longer disease duration than MSA-P patients, and PSP patients had higher MDS-UPDRS-III and H-Y scores than others (P < 0.05). In addition, PSP patients had lower MoCA scores than PD and MSA patients (P < 0.05) (Table 1). Detailed comparisons between early- and advanced-stage PD are listed in Supplementary Table 1.Table 1 Demographic, clinical characteristics and 11C-CFT PET/CT data of all patients

	PD	MSA-P	PSP	VP	P value	
Number	80	54	15	17	–	
Sex(male/female)	31/49	24/30	8/7	11/6	0.229	
Age(year)	62.75 ± 10.92	60.39 ± 8.57c	65.07 ± 3.94	69.29 ± 5.52	0.006*	
Disease duration(year)	5.70 ± 3.22a	4.07 ± 1.78	4.93 ± 1.53	4.82 ± 1.24	0.005*	
H-Y	2.13 ± 0.95b	2.31 ± 0.77b	3.17 ± 1.03	2.06 ± 0.43b	<0.001*	
MDS-UPDRS-III	31.23 ± 19.24b	36.83 ± 17.95b	51.87 ± 14.35	28.24 ± 9.00b	<0.001*	
MoCA	21.54 ± 4.77b	21.63 ± 4.00b	17.20 ± 3.45	21.06 ± 4.43	0.004*	
11C-CFT SUVR	
Caudate	1.59 ± 0.38b, c	1.51 ± 0.34c	1.26 ± 0.92c	1.82 ± 0.47	0.010*	
Anterior Putamen	2.09 ± 0.45c	1.99 ± 0.39c	1.84 ± 0.76c	2.42 ± 0.73	0.018*	
Posterior Putamen	1.80 ± 0.43c	1.70 ± 0.34c	1.59 ± 0.46c	2.26 ± 0.71	<0.001*	
Asymmetry Index, %	
Caudate	9.37 ± 7.48	6.93 ± 5.93	6.63 ± 4.67	6.01 ± 6.20	0.092	
Anterior Putamen	13.86 ± 7.61a, b, c	10.71 ± 7.28	10.45 ± 7.39	9.02 ± 7.09	0.003*	
Posterior Putamen	10.30 ± 8.35	8.20 ± 5.50	7.43 ± 6.59	8.13 ± 8.00	0.305	
Data are given as mean ± SD. P values of 11C-CFT uptake were calculated by generalized linear model, adjusting for MDS-UPDRS-III, MoCA, disease duration, age and H-Y.

PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism, H-Y Hoehn-Yahr scale, MDS-UPDRS-III Movement Disorder Society Unified Parkinson Disease Rating Scale part III, MoCA Montreal Cognitive Assessment, SUVR standardized uptake value ratio.

*P < 0.05. In post hoc, aP < 0.05 vs. MSA-P, bP < 0.05 vs. PSP, cP < 0.05 vs. VP.

11C-CFT uptake and asymmetry indices

No apparent reduction in 11C-CFT uptake was observed in patients with VP. Patients with PD and MSA-P showed a lower uptake than those with VP, with a similar degree of decline. Patients with PSP had notably lower uptake than other patients (Fig. 1a). After correcting for MDS-UPDRS-III, MoCA, disease duration, age, and H-Y, significant differences were observed in the caudate (P = 0.010), anterior (P = 0.018) and posterior putamen (P < 0.001). A post-hoc analysis indicated substantial differences in the caudate, anterior and posterior putamen between the uptake values of VP patients and those of other patients (P < 0.05; Table 1, Fig. 2a, Supplementary Tables 4–6). Asymmetry indices were further found to be higher in PD patients than in other patients, especially in the anterior putamen (P = 0.003; Table 1, Fig. 2b, Supplementary Tables 7–9).Fig. 1 11C-CFT and 18F-FDG PET/CT images.

a 11C-CFT uptake images. PD patient shows asymmetrical 11C-CFT uptake reduction; MSA-P patient showed a relatively symmetrical reduction in 11C-CFT uptake that was slightly greater than that observed in PD patient; PSP patient showed significant bilateral uptake reduction; VP patient shows non-significant 11C-CFT uptake reduction. The arrows in Fig. 1a indicate the portion with a reduced uptake. b Schematic diagram of the automatic segmentation of each ROI in 11C-CFT PET/CT. Green represents caudate, yellow represents anterior putamen, red represents posterior putamen, and blue represents occipital lobe. c 18F-FDG Z-score images. PD patient shows hypometabolism in the prefrontal and parieto-occipital cortices, and hypermetabolism in the cerebellum and pons; MSA-P patient shows hypometabolism in the cerebellum and pons; PSP patient shows hypometabolism in the prefrontal and parieto-occipital cortices. The marker at the bottom changed from black to red, indicating a gradual decrease in the Z-score. d 18F-FDG Z-score images of putamen, caudate and thalamus. PD patient shows hypermetabolism in the thalamus and putamen; MSA-P patient shows hypometabolism in the caudate, thalamus and putamen; PSP patient shows hypometabolism in the putamen and thalamus. The marker on the right changed from blue to red, indicating a gradual increase in the Z-score. Z-score >0, hypermetabolism; Z-score <0, hypometabolism. 18F-FDG images of VP patients were not obtained because of the non-specificity of FDG metabolism in VP patients. PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism.

Fig. 2 11C-CFT SUVR, asymmetry indices, and 18F-FDG Z-score of patients with PD (n = 80), MSA-P (n = 54), PSP (n = 15), and VP (n = 17).

a Comparison of 11C-CFT SUVR values among groups. b Comparison of asymmetry index among groups. P values were obtained by generalized linear models, and error bars were generated from the standard deviation. c Box-plots of the Z-score of PD, MSA-P, and PSP. Each box represents the distribution of Z-score in that region of interest (ROI) for that group of patients. The yellow markings in the figure represent brain regions with P < 0.001, while the remaining statistically significant ROIs are detailed in Supplementary Table 2. Centerline, medians; box limits, upper and lower quartiles; whisker, 1.5× interquartile ranges; points, outliers; Z-score >0, hypermetabolism; Z-score <0, hypometabolism. PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism, AP anterior putamen, PP posterior putamen, SUVR standardized uptake value ratio, R right, L left; *P < 0.05.

Characteristic patterns of glucose metabolism in 18F-FDG PET/CT

Compared with normal database in the CortexID Suite and hospital physical examination center, PD patients showed notable hypometabolism in the lateral occipital, parietal, precuneus, sensorimotor, and lateral prefrontal cortices, with significant hypermetabolism in the cerebellum, pons, mesial temporal cortex, caudate and putamen. Patients with MSA-P showed significant hypermetabolism in the primary visual cortex and significant hypometabolism in the cerebellum, pons, prefrontal and parietal cortices, caudate, putamen and thalamus. PSP patients showed hypermetabolism in the mesial temporal cortex and hypometabolism in the anterior and posterior cingulate, inferior parietal, prefrontal, precuneus, sensorimotor cortices, thalamus and caudate (P < 0.05; Figs. 1c, d and 2c; Supplementary Table 2).

After correcting for MDS-UPDRS-III, MoCA, age, H-Y, and disease duration, we observed significant differences in Z-score between PD and MSA-P patients in the sensorimotor, primary visual, mesial temporal, precuneus, parietal, lateral occipital cortices, pons, cerebellum, caudate, putamen and thalamus, and between PD and PSP patients in the medial prefrontal, anterior cingulate, inferior parietal, lateral occipital cortices, caudate, putamen and thalamus (P < 0.05; Table 2, Fig. 3b, Supplementary Tables 10–43).Table 2 Comparison of 18F-FDG Z-Score in PD vs. MSA-P and PSP

Region of interest	PD	MSA-P	PSP	P1 Value	P2 Value	
Prefrontal lateral	−1.51 ± 1.95	−1.16 ± 1.83	−2.45 ± 1.41	0.363	0.128	
Prefrontal medial	−0.28 ± 1.62	−0.62 ± 1.81	−2.19 ± 1.61	0.309	<0.001*	
Sensorimotor	−2.31 ± 1.90	−0.33 ± 1.84	−1.01 ± 1.49	<0.001*	0.056	
Anterior cingulate	0.36 ± 1.38	0.01 ± 1.15	−1.55 ± 1.20	0.105	<0.001*	
Posterior cingulate	−0.26 ± 1.27	0.05 ± 1.27	−1.01 ± 1.58	0.066	0.088	
Precuneus	−1.36 ± 1.54	0.12 ± 1.56	−1.52 ± 1.35	<0.001*	0.829	
Parietal superior	−2.89 ± 1.61	−1.01 ± 1.57	−1.36 ± 1.93	<0.001*	0.051	
Parietal inferior	−4.07 ± 1.39	−2.20 ± 1.41	−2.30 ± 0.97	<0.001*	<0.001*	
Occipital lateral	−1.80 ± 2.01	0.30 ± 1.98	0.30 ± 2.13	<0.001*	<0.001*	
Primary visual	0.23 ± 1.57	1.29 ± 1.61	0.71 ± 1.64	0.001*	0.132	
Temporal lateral	0.45 ± 1.62	0.31 ± 1.83	0.71 ± 1.32	0.994	0.052	
Temporal mesial	2.21 ± 2.09	0.66 ± 1.99	1.18 ± 1.72	<0.001*	0.100	
Cerebellum whole	1.00 ± 1.20	−2.67 ± 1.89	0.30 ± 1.76	<0.001*	0.154	
Pons	1.18 ± 1.29	−2.88 ± 2.43	0.58 ± 1.60	<0.001*	0.142	
Caudate	0.39 ± 0.78	−1.07 ± 0.88	−1.42 ± 1.51	<0.001*	<0.001*	
Putamen	0.63 ± 1.08	−1.33 ± 1.75	−0.10 ± 1.16	<0.001*	0.010*	
Thalamus	0.11 ± 1.12	−0.93 ± 1.22	−1.55 ± 1.53	<0.001*	<0.001*	
Data are given as mean ± SD. P values were calculated by generalized linear model, adjusting for MDS-UPDRS-III, MoCA, disease duration, age and H-Y. The Z-score is the dispersion of the patient’s 18F-FDG metabolic values obtained using the CortexID Suite software and SNBPI toolbox compared with the normal database.

PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, P1 PD verse MSA, P2 PD verse PSP.

*P < 0.05.

Fig. 3 ROC curves for 11C-CFT, 18F-FDG PET/CT and the combination of the two scans.

a Histogram of 11C-CFT standardized uptake value ratio (SUVR) in patients with early-stage PD (n = 46), advanced-stage PD (n = 34), and PSP (n = 15), as well as the receiver operating characteristic (ROC) curves for 11C-CFT PET/CT. The distribution of 11C-CFT SUVRs for PD, MSA-P, and VP are shown in Fig. 2a. b Z-score violin plots of ROIs with statistical differences for PD vs. MSA-P and PSP in 18F-FDG PET/CT and the ROC curves for 18F-FDG PET/CT. The comparison results in the violin plot are detailed in Table 2. Centerline, median; bilateral lines, upper and lower quartiles. c Principal components (PC) plots of PD vs. MSA-P and PD vs. PSP and the ROC curves for the combination of the two scans. Principal component analysis was performed on the combination of SUVRs of three ROIs in 11C-CFT PET/CT and Z-score of ROIs shown in Fig. 3b in 18F-FDG PET/CT, and two PCs were obtained. Due to the lack of specificity of 18F-FDG PET/CT in the diagnosis of VP, it was not included in the ROC analysis of 18F-FDG PET/CT and the combination of both scans. The areas under the curve (AUC) and their 95% confidence intervals are shown. PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism, Combination, the combination of 11C-CFT and 18F-FDG PET/CT.

Combination of 11C-CFT and 18F-FDG data

Using PCA to analyze the uptake values of the three ROIs in 11C-CFT PET/CT and the Z-scores of ROIs with statistically differences in PD compared with PSP and MSA-P in 18F-FDG PET/CT, which ultimately yielded two principal components (PCs). These two PCs effectively separated PD from MSA-P and PSP (Fig. 3c).

Diagnostic efficacy of 11C-CFT and 18F-FDG PET/CT

The AUCs for 11C-CFT PET/CT in distinguishing PD from MSA-P, PSP, and VP were 0.580 (95% confidence interval, 0.482–0.678), 0.830 (0.701–0.959) and 0.902 (0.842–0.962), respectively, suggesting that 11C-CFT PET/CT alone is sufficient to distinguish PD from VP. This is not surprising as the VP does not have any structural lesions in the nigrostriatal system. For this reason, and because 18F-FDG PET/CT has a low specificity for VP, we did not calculate the diagnostic efficacy of 18F-FDG PET/CT alone or the efficacy of combined scans for differentiating PD from VP. Although the AUC for 11C-CFT PET/CT to differentiate PD from PSP was reasonably high (0.830), the AUCs for differentiating early- and advanced-stage PD from PSP were 0.862 (0.729–0.995) and 0.728 (0.573–0.882), respectively, indicating that it is more difficult to differentiate advanced-stage PD from PSP using this modality alone (Fig. 3a). The AUCs for using 18F-FDG PET/CT alone to differentiate PD from MSA-P and PSP were 0.963 (0.935–0.990) and 0.968 (0.925–1.000), respectively (Fig. 3b), while the AUCs combining the two modalities were 0.969 (0.946–0.993) and 0.978 (0.949–1.000), respectively (Fig. 3c).

When clinical indicators, including MDS-UPDRS-III, MoCA, disease duration, age, and H-Y were combined with 11C-CFT PET/CT, the AUCs for differentiating PD from MSA-P, PSP, and VP improved to 0.745 (0.661–0.829), 0.858 (0.758–0.958), and 0.935 (0.886–0.984), respectively; and the AUCs for discriminating PSP from early- and advanced-stage PD were 0.996 (0.986–1.000) and 0.790 (0.666–0.915), respectively (Fig. 4a). When clinical indicators were combined with 18F-FDG PET/CT, the AUCs for distinguishing PD from MSA-P and PSP were 0.967 (0.941–0.993) and 0.976 (0.947–1.000), respectively (Fig. 4b). When clinical indicators are combined with these two scans, the AUCs for distinguishing PD from MSA-P, PSP increased further to 0.972 (0.949–0.995) and 0.998 (0.992–1.000), respectively (Fig. 4c).Fig. 4 ROC curves for clinical indicators in combination with PET/CT.

a Receiver operating characteristic (ROC) curves for the combination of clinical indications with 11C-CFT PET/CT. b ROC curves for the combination of clinical indications with 18F-FDG PET/CT. c ROC curves for the combination of clinical indications with these two PET/CT scans. Clinical indicators include MDS-UPDRS-III, MoCA, H-Y, disease duration, and age. The areas under the curve (AUC) and their 95% confidence intervals are shown. PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism, Combination, the combination of 11C-CFT and 18F-FDG PET/CT.

The sensitivity, specificity, and agreement rate for the PD diagnosis were 74%, 87% and 81%, respectively, when 11C-CFT PET/CT was used; 96%, 92% and 94%, respectively, when using 18F-FDG PET/CT; and 84%, 89% and 84%, respectively, when both scans were combined. The sensitivity, specificity, and agreement rate for the MSA-P diagnosis were 74%, 89% and 84%, respectively, when using 11C-CFT PET/CT alone; 93%, 95% and 94%, respectively, when using 18F-FDG PET/CT alone; and 89%, 96% and 93%, respectively, when using both scans. The sensitivity, specificity, and agreement rate for the PSP diagnosis were 73%, 98% and 95%, respectively, when 11C-CFT PET/CT was used; 80%, 100% and 98%, respectively, when using 18F-FDG PET/CT; and 80%, 100% and 98%, respectively, when both scans were used. The sensitivity, specificity, and agreement rate for the VP diagnosis were 94%, 91% and 92%, respectively, when 11C-CFT PET/CT was used (Supplementary Table 3).

The consistency between the clinical and 11C-CFT PET/CT diagnoses was moderate (κ = 0.640, P < 0.001). The consistencies between clinical diagnosis and 18F-FDG PET/CT diagnosis, and between clinical diagnosis and diagnosis of these two scans were good (κ = 0.885, P < 0.001).

Discussion

11C-CFT is a radioactive tracer which specifically binds to dopamine transporters on the plasma membrane of dopaminergic neuron terminals in the striatum17,18. The level of binding reflects the degree of damage to the dopaminergic neurons in the nigrostriatal system19. In the present study, patients with VP showed no obvious 11C-CFT uptake reduction, indicating that the nigrostriatal system was intact. However, 11C-CFT uptake has shown various degrees of dopaminergic neuronal damage in PD, MSA-P, and PSP patients, consistent with their neuropathology20,21, suggesting that 11C-CFT PET/CT could detect changes in central dopaminergic neuron function with a high degree of sensitivity8. Similar reductions in PD and MSA-P patients likely reflect similar degrees of dopaminergic neuron loss in these patients. Additionally, in line with previous findings22, we observed a lower uptake (reflecting more severe dopaminergic system dysfunction) in PSP patients than in PD and MSA-P patients.

Clinically, PD typically initiates with unilateral motor symptoms, maintaining some degree of asymmetry throughout disease progression, whereas most MSA-P and PSP patients display more symmetrical clinical symptoms23. In the present study, the asymmetry indices were found to be higher in PD than in others; however, this difference was mostly limited to the anterior putamen. Similarly, Pirker24 reported that the visual examination of PET/CT images revealed more symmetrical uptake in MSA and PSP patients than in PD patients; however, these differences were not significant. Further studies with more participants are required to clarify these characteristics.

In short, our results showed that 11C-CFT PET/CT is a highly effective method for distinguishing PD from PD-like disorders with an intact nigrostriatal system, such as ET and VP25. However, this modality alone is insufficiently sensitive to differentiate PD from MSA-P or advanced-stage PD from PSP because of a similar reduction in 11C-CFT uptake values, reflecting the overlapping pathological lesions between these diseases. When 11C-CFT PET/CT was combined with clinical indicators, the diagnostic accuracy improved to some extent, but was still not ideal for distinguishing PD from MSA-P (AUC = 0.745) and advanced-staged PD form PSP (AUC = 0.790).

Using 18F-FDG tracer, different diseases have been shown to have disease-specific metabolic patterns linked to functional changes in different brain regions. In contrast to previous studies that used visual image reading techniques or voxel-based spatial covariance methods to diagnose various disorders without considering variations in uptake values throughout the whole brain14,26–28, we used CortexID Suite software and the SNBPI toolbox to quantitatively analyze the ROIs of 18F-FDG PET images. When compared with the normal database, we identified several disease-specific glucose metabolic patterns for PD, MSA-P and PSP, consistent with previous studies14,29,30. Furthermore, we observed differences in Z-score among brain regions in various diseases. Overall, PD patients showed more significant hypometabolism in the sensorimotor, precuneus, lateral occipital, and parietal cortices, and hypermetabolism in the caudate, thalamus, putamen, mesial temporal cortex, cerebellum, and pons. MSA-P patients had significant hypometabolism in the caudate, thalamus, putamen, cerebellum and pons, and PSP patients had more obvious hypometabolism in the anterior cingulate, medial prefrontal cortices, caudate, thalamus and putamen. Finally, we evaluated diagnostic efficacy using the statistically significant ROIs listed above and found that the diagnostic efficacy was high with all AUCs exceeded 0.90, indicating that 18F-FDG PET/CT outperformed 11C-CFT PET/CT in distinguishing PD from PSP and MSA-P.

Based on these findings, we recommend performing both 11C-CFT and 18F-FDG PET/CT to achieve an accurate differential diagnosis of PD and related diseases. In clinical practice, we suggest the initial identification of dopaminergic neuron degeneration by 11C-CFT PET/CT to differentiate PD from ET and VP, which present with PD-like symptoms but have no typical pathological lesions in the nigrostriatal system, followed by 18F-FDG PET/CT to identify disease-specific metabolism pattern for further distinction between PD, MSA-P and PSP. Considering financial cost, among patients in whom ET and VP can be ruled out, as well as those with typical extrapyramidal symptoms indicating nigrostriatal pathology, 18F-FDG PET/CT alone is also a good choice.

This study had some limitations. First, the number of VP and PSP patients was relatively small. Future research with more participants is required to examine the relationships between the uptake values and clinical indices in these groups with higher statistical power. Second, this study was a single-center study. In the future, further multi-center research is required to confirm the findings.

In conclusion, we found that 11C-CFT PET/CT accurately detects dopaminergic axonal loss in the striatum, thereby enabling the differentiation of PD from VP, but had a limited ability to differentiate PD from PSP and MSA-P. 18F-FDG PET/CT is highly sensitive for differentiating PD from PSP and MSA-P by revealing disease-specific metabolic patterns. The combination of these two imaging modalities will help improve the diagnostic accuracy and guide treatment strategies.

Methods

Participants and design

In this study, we enrolled 220 patients with PD-like symptoms between 2019 and 2022. Of these, 54 were excluded due to their inability to complete PET/CT scans or neuropsychological measurements; finally, 166 patients were ultimately included in our study. Of the study cohort, 80 patients were diagnosed PD according to the 2015 MDS PD diagnostic criteria6 (46 with early-stage PD; 34 with advanced-stage PD; early-stage, H-Y ≤ 2; advanced-stage, H-Y > 231), while 54 were diagnosed with MSA-P32, 15 with PSP33, and 17 with VP34. To determine the final clinical diagnosis, specialists followed each patient for at least two years following the initial diagnosis. Patients with clearly signs of mental illness (e.g., depression), those on long-term antipsychotic drugs (as some antipsychotic drugs may cause patients to develop PD-like symptoms that can confound study results, such as fluoxetine), those who underwent deep brain stimulation surgery, those with severe organ (heart, liver, or kidney) damage, and those with structural imaging suggestive of lesions in the basal ganglia region were all excluded. Demographic and clinical data were collected, and all patients underwent 11C-CFT and 18F-FDG PET/CT. Subsequently, receiver operating characteristic (ROC) curves were plotted to estimate the value of PET/CT in the differential diagnosis of PD. A flowchart of the study is presented in Fig. 5.Fig. 5 Research flowchart.

Diagnosis and analysis process for all participants. PD Parkinson’s disease, MSA-P multiple system atrophy parkinsonian type, PSP progressive supranuclear palsy, VP vascular parkinsonism.

The Jilin University First Hospital of Bethune Ethical Review Board approved this study (NO. 2024-441), and all patients signed informed consent forms.

Motor and neuropsychological assessment

One neurologist performed the neuropsychological assessments. In the “off” state, we used the part III of MDS Unified Parkinson Disease Rating Scale (MDS-UPDRS-III) and Hoehn-Yahr scale (H-Y) to assess the severity of motor symptoms. Further, we used the Montreal Cognitive Assessment (MoCA) to assess the cognitive function of patients in the “on” state.

PET/CT imaging process

11C-CFT and 18F-FDG with ≥95% radiochemical purity were produced using an HM-12 cyclotron (Sumitomo Heavy Industries, Ltd., Kyoto, Japan). Brain PET/CT examinations were performed using a Siemens Discovery 16HR PET/CT (Siemens, Berlin, Germany). All patients fasted for at least 6 h, and discontinued dopaminergic drugs for at least 12 h prior to the scan. An 11C-CFT PET scan lasting 10 min was started 60 min35 following the intravenous injection of 370 MBq36 of 11C-CFT; and an 18F-FDG PET scan of 10 min was started 60 min37 after the intravenous injection of 3.7 MBq/Kg28 of 18F-FDG. All participants were asked to remain in a quiet, dark environment before the scan. We used a head rest to hold the patient’s head motionless during the scanning process to prevent head movements from affecting the results. Two PET examinations were completed within one week. A CT scan of the brain was initially conducted using a fixed tube voltage of 120 kV (tube current 100 mA) for attenuation correction and anatomical localization, followed by a PET scan in the 3D mode. The attenuation of PET images was finally corrected using CT data, followed by iterative image reconstruction to obtain cross-sectional, coronal, sagittal CT, PET, and PET/CT images. Using the 3D ordered-subset expectation maximization (OSEM) algorithm (4 iterations, 24 subsets; Gaussian filter: 2 mm; zoom: 3; thickness: 3 mm; FOV: 585 mm*162 mm), PET images were reconstructed using the manufacturer’s scatter, and random correction in addition to CT-based attenuation correction was performed. The reconstructed images measured 0.68 × 0.68 × 1.5 mm in voxel size and 400 × 400 × 148 in matrix size.

PET/CT analysis

The 11C-CFT PET/CT brain data were processed with toolbox Spatial Normalization of Brain PET Images (SNBPI; https://github.com/IHEP-Brain-Imaging/Spatial-Normalization-of-Brain-PET-Images; Chinese Academy of Sciences, Beijing, China)38 running on MATLAB 2022a (MathWorks Inc., Sherborn, MA). Using the SNBPI toolbox, which is based on the DARTEL method, each patient’s scan was spatially normalized into the Montreal Neurological Institute (MNI) brain space, and subsequently resliced to 2-2-2 mm, after which SPM12 (Statistical Parametric Mapping; Wellcome Department of Imaging Neuroscience, London, UK) using an isotropic 3D Gaussian kernel (FWHM = 8-8-8 mm) was applied to smooth. Anatomical automatic labeling (AAL) atlas was used to extract the region of interest (ROI) of each patient’s bilateral caudate, anterior and posterior putamen, and occipital lobe using the SNBPI toolbox (Fig. 1b). In the AAL atlas, the putamen is automatically separated into two equally sized segments. The first half was identified as the anterior putamen, and the second as the posterior putamen. The mean standardized uptake value ratio (SUVR) values were then automatically calculated for the ROIs. The occipital lobe was used as a background reference. Each ROI’s SUVR was computed using this formula: (striatum-occipital)/occipital count. The average SUVR values were then obtained from the values calculated for both sides of the caudate, and the anterior and posterior putamen. The asymmetry of the SUVR values in the bilateral striatum was expressed using the asymmetry index39: (high-side value – low-side value)/high-side value × 100%.

18F-FDG PET/CT images were analyzed using CortexID Suite (GE Healthcare, Marlborough, MA, USA). Using this software, a 3D stereotactic surface projection (3D-SSP) method (Seattle, Washington, USA) are used, which automatically normalizes the brain anatomy by combining rotational corrections and stereotactic transformations to extract peaks of cortical activity from a predefined set of pixels on the brain surface40. This activity was compared with that of an age-matched database of normal subjects (Z-score = 0) using Z-score subtraction, which yield hypometabolic (Z-score) maps in eight standard directions. The ROI was defined automatically in 26 regions, including the bilateral lateral and medial prefrontal and temporal, sensorimotor, precuneus, inferior and superior parietal, anterior and posterior cingulate, occipital, primary visual cortices, whole cerebellum and pons. The SUVR was further calculated with the whole-brain mean values serving as the reference41. The Z-scores denoting the deviation from the normal data were computed as follows: (SUVRsubj − SUVRnormal)/SDnormal, where SUVRsubj is the mean SUVR of the study subject, SUVRnormal is the mean SUVR from the normal subject database, and SDnormal is the standard deviation of the SUVR from the normal subject database42. We subsequently obtain the average value of Z-score on both sides of each ROI.

The metabolism of the caudate, putamen and thalamus on 18F-FDG PET/CT was analyzed using toolbox SNBPI38 running on MATLAB 2022a. Each image was spatially normalized to MNI space based on DARTEL algorithm and resliced to 2-2-2 mm. Then utilizing SPM12 to smooth using an isotropic 3D Gaussian kernel (FWHM = 8-8-8 mm). The ROIs of the bilateral putamen, caudate and thalamus for each patient were retrieved from the AAL atlas. The whole brain was selected as the reference area to automatically calculate the SUVR. The mean SUVR value was automatically calculated for each ROI. In addition, 43 age-matched healthy individuals from the Physical Examination Center of the First Hospital of Jilin University were selected as the normal control group and their SUVRs for each ROI were calculated. The Z-scores were calculated using the Z-score formula described above.

Statistical methods

SPSS 26 (IBM Corporation, Armonk, NY, USA) was used to analyze the data. The Shapiro–Wilk test was used to ascertain the normality of quantitative data. Demographic and clinical characteristics were compared using analysis of variance (ANOVA), followed by Bonferroni post-hoc analysis. Generalized linear models were further employed to compare 11C-CFT uptake values among the groups and 18F-FDG Z-scores for PD versus MSA-P and PD versus PSP, correcting for the effects of MDS-UPDRS-III, MoCA, age, disease duration, and H-Y. One-sample t-test was used to assess the distribution of Z-score for different diseases relative to the normal database using CortexID Suite software and the Physical Examination Center of the First Hospital of Jilin University (Z-score = 0). Principal component analysis (PCA) was performed on the combination of uptake values of the three ROIs in 11C-CFT PET/CT and the Z-scores of the ROIs with statistically differences in PD compared to MSA-P and PSP obtained from the generalized linear models in 18F-FDG PET/CT. Evaluation of the diagnostic value of PET/CT was further performed to facilitate the differential diagnosis of PD using ROC curves and aera under the curve (AUC). Using binary logistic regression, disease groupings were used as dependent variables, and imaging metrics to be combined (uptake values of the caudate, anterior and posterior putamen in 11C-CFT and Z-scores of the ROIs that differed between the two groups obtained in the generalized linear model in 18F-FDG) were used as covariates to compute the predictive probability, while ROC curves were plotted using the predictive probability. Using the identified metabolic patterns of the disease as PET/CT diagnostic criteria, we calculated the sensitivity, specificity, and agreement rate. The Kappa test was used to evaluate the coincidence between PET/CT findings and clinical diagnoses. Statistical significance was set at P < 0.05.

Supplementary information

Supplemental Material

Supplementary information

The online version contains supplementary material available at 10.1038/s41531-024-00786-z.

Acknowledgements

The work was supported by the First Hospital of Jilin University. We thank Professor Yanhua Wu for her help in statistical analysis and Professor Binbin Nie for her help in automated analysis of PET/CT images. The work was supported by grants from the National Natural Science Foundation of China (No. 81974194), the Natural Science Foundation of Jilin Province (No. YDZJ202201ZYTS116), Jilin Province Department of Finance Project (No. JLSWSRCZX2020-0011) and Jilin Province Health and Technology Innovation Project (No. 2018J045) to Y.Z.

Author contributions

X.X.D.: conception, methodology, data acquisition, analysis, interpretation of the results, writing of the original draft; H.G.Z.: methodology, interpretation of the results, revision of the manuscript for intellectual content; Y.H.L.: methodology, interpretation of the results; Y.Y.D.: methodology, interpretation of the results; Y.L.: data acquisition, analysis; K.L.F.: data acquisition, analysis; Z.H.S.: data acquisition, analysis; Y.Z.: conception, methodology, interpretation of the results, supervision, revision of the manuscript for intellectual content. All authors read and approved the final manuscript. X.X.D. and H.G.Z. are considered co-first author.

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. The data were not publicly available due to privacy or ethical restrictions.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xiaoxiao Du, Hongguang Zhao.
==== Refs
References

1. Tolosa E Garrido A Scholz SW Poewe W Challenges in the diagnosis of Parkinson’s disease Lancet Neurol. 2021 20 385 397 10.1016/S1474-4422(21)00030-2 33894193
Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 20, 385–397 (2021).33894193 10.1016/S1474-4422(21)00030-2
2. Seiffert AP Differences in Striatal Metabolism in [18F] FDG PET in Parkinson’s Disease and Atypical Parkinsonism Diagnostics 2022 13 6 10.3390/diagnostics13010006 36611298
Seiffert, A. P. et al. Differences in Striatal Metabolism in [18F] FDG PET in Parkinson’s Disease and Atypical Parkinsonism. Diagnostics 13, 6 (2022).36611298 10.3390/diagnostics13010006
3. Armstrong MJ Okun MS Diagnosis and Treatment of Parkinson Disease: A Review JAMA 2020 323 548 560 10.1001/jama.2019.22360 32044947
Armstrong, M. J. & Okun, M. S. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA 323, 548–560 (2020).32044947 10.1001/jama.2019.22360
4. Golan H Volkov O Shalom E Nuclear imaging in Parkinson’s disease: The past, the present, and the future J. Neurol. Sci. 2022 436 120220 10.1016/j.jns.2022.120220 35313223
Golan, H., Volkov, O. & Shalom, E. Nuclear imaging in Parkinson’s disease: The past, the present, and the future. J. Neurol. Sci. 436, 120220 (2022).35313223 10.1016/j.jns.2022.120220
5. Peralta C Biafore F Depetris TS Bastianello M Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson’s Disease, Atypical Parkinsonisms, and Other Movement Disorders Curr. Neurol. Neurosci. Rep. 2019 19 56 10.1007/s11910-019-0966-3 31256288
Peralta, C., Biafore, F., Depetris, T. S. & Bastianello, M. Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson’s Disease, Atypical Parkinsonisms, and Other Movement Disorders. Curr. Neurol. Neurosci. Rep. 19, 56 (2019).31256288 10.1007/s11910-019-0966-3
6. Postuma RB MDS clinical diagnostic criteria for Parkinson’s disease Mov. Disord. 2015 30 1591 1601 10.1002/mds.26424 26474316
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).26474316 10.1002/mds.26424
7. Sun XL (11)C-CFT PET brain imaging in Parkinson’s disease using a total-body PET/CT scanner EJNMMI Phys. 2024 11 40 10.1186/s40658-024-00640-4 38662044
Sun, X. L. et al. (11)C-CFT PET brain imaging in Parkinson’s disease using a total-body PET/CT scanner. EJNMMI Phys. 11, 40 (2024).38662044 10.1186/s40658-024-00640-4
8. Xin M Exploring the nigrostriatal and digestive interplays in Parkinson’s disease using dynamic total-body [(11)C] CFT PET/CT Eur. J. Nucl. Med. Mol. Imaging 2024 51 2271 2282 10.1007/s00259-024-06638-5 38393375
Xin, M. et al. Exploring the nigrostriatal and digestive interplays in Parkinson’s disease using dynamic total-body [(11)C] CFT PET/CT. Eur. J. Nucl. Med. Mol. Imaging 51, 2271–2282 (2024).38393375 10.1007/s00259-024-06638-5
9. Xie LJ Zhao JH Li Y Bai J PET brain imaging in neurological disorders Phys. Life Rev. 2024 49 100 111 10.1016/j.plrev.2024.03.007 38574584
Xie, L. J., Zhao, J. H., Li, Y. & Bai, J. PET brain imaging in neurological disorders. Phys. Life Rev. 49, 100–111 (2024).38574584 10.1016/j.plrev.2024.03.007
10. Ko JH Lee CS Eidelberg D Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations J. Cereb. Blood Flow. Metab. 2017 37 683 693 10.1177/0271678X16637880 26980757
Ko, J. H., Lee, C. S. & Eidelberg, D. Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. J. Cereb. Blood Flow. Metab. 37, 683–693 (2017).26980757 10.1177/0271678X16637880
11. Liu FT Clinical, Dopaminergic, and Metabolic Correlations in Parkinson Disease: A Dual-Tracer PET Study Clin. Nucl. Med. 2018 43 562 571 10.1097/RLU.0000000000002148 29863572
Liu, F. T. et al. Clinical, Dopaminergic, and Metabolic Correlations in Parkinson Disease: A Dual-Tracer PET Study. Clin. Nucl. Med. 43, 562–571 (2018).29863572 10.1097/RLU.0000000000002148
12. Chen QS Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes Acta Neurol. Scand. 2022 146 237 245 10.1111/ane.13653 35611608
Chen, Q. S. et al. Dopamine transporter imaging in progressive supranuclear palsy: Severe but nonspecific to subtypes. Acta Neurol. Scand. 146, 237–245 (2022).35611608 10.1111/ane.13653
13. Ruppert MC Network degeneration in Parkinson’s disease: multimodal imaging of nigro-striato-cortical dysfunction Brain 2020 143 944 959 10.1093/brain/awaa019 32057084
Ruppert, M. C. et al. Network degeneration in Parkinson’s disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain 143, 944–959 (2020).32057084 10.1093/brain/awaa019
14. Tang CC Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis Lancet Neurol. 2010 9 149 158 10.1016/S1474-4422(10)70002-8 20061183
Tang, C. C. et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 9, 149–158 (2010).20061183 10.1016/S1474-4422(10)70002-8
15. Niethammer M A disease-specific metabolic brain network associated with corticobasal degeneration Brain 2014 137 3036 3046 10.1093/brain/awu256 25208922
Niethammer, M. et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 137, 3036–3046 (2014).25208922 10.1093/brain/awu256
16. Meles SK Oertel WH Leenders KL Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease Mol. Med. 2021 27 111 10.1186/s10020-021-00327-x 34530732
Meles, S. K., Oertel, W. H. & Leenders, K. L. Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease. Mol. Med. 27, 111 (2021).34530732 10.1186/s10020-021-00327-x
17. Xie LL Hu LD Research progress in the early diagnosis of Parkinson’s disease Neurol. Sci. 2022 43 6225 6231 10.1007/s10072-022-06316-0 35948779
Xie, L. L. & Hu, L. D. Research progress in the early diagnosis of Parkinson’s disease. Neurol. Sci. 43, 6225–6231 (2022).35948779 10.1007/s10072-022-06316-0
18. Xu JH Computer-Aided Classification Framework of Parkinsonian Disorders Using (11)C-CFT PET Imaging Front. Aging Neurosci. 2021 13 792951 10.3389/fnagi.2021.792951 35177974
Xu, J. H. et al. Computer-Aided Classification Framework of Parkinsonian Disorders Using (11)C-CFT PET Imaging. Front. Aging Neurosci. 13, 792951 (2021).35177974 10.3389/fnagi.2021.792951
19. Kangli F Characteristics and influencing factors of 11C-CFT PET imaging in patients with early and late onset Parkinson’s disease Front. Neurol. 2023 14 1195577 10.3389/fneur.2023.1195577 37483437
Kangli, F. et al. Characteristics and influencing factors of 11C-CFT PET imaging in patients with early and late onset Parkinson’s disease. Front. Neurol. 14, 1195577 (2023).37483437 10.3389/fneur.2023.1195577
20. Dickson DW Neuropathology of Parkinson disease Parkinsonism Relat. D. 2018 46 S30 S33 10.1016/j.parkreldis.2017.07.033
Dickson, D. W. Neuropathology of Parkinson disease. Parkinsonism Relat. D. 46, S30–S33 (2018).10.1016/j.parkreldis.2017.07.033
21. Jellinger KA Neuropathology of multiple system atrophy: New thoughts about pathogenesis Mov. Disord. 2014 29 1720 1741 10.1002/mds.26052 25297524
Jellinger, K. A. Neuropathology of multiple system atrophy: New thoughts about pathogenesis. Mov. Disord. 29, 1720–1741 (2014).25297524 10.1002/mds.26052
22. Chen MJ Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy Front. Aging Neurosci. 2022 14 998255 10.3389/fnagi.2022.998255 36092815
Chen, M. J. et al. Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy. Front. Aging Neurosci. 14, 998255 (2022).36092815 10.3389/fnagi.2022.998255
23. Fearnley JM Lees AJ Striatonigral degeneration. A clinicopathological Brain 1990 113 1823 1842 10.1093/brain/113.6.1823 2276046
Fearnley, J. M. & Lees, A. J. Striatonigral degeneration. A clinicopathological. Brain 113, 1823–1842 (1990).2276046 10.1093/brain/113.6.1823
24. Pirker W 123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration Mov. Disord. 2000 15 1158 1167 10.1002/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0 11104200
Pirker, W. et al. 123I] beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov. Disord. 15, 1158–1167 (2000).11104200 10.1002/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0
25. Bidesi NSR Vang Andersen I Windhorst AD Shalgunov V Herth MM The role of neuroimaging in Parkinson’s disease J. Neurochem. 2021 159 660 689 10.1111/jnc.15516 34532856
Bidesi, N. S. R., Vang Andersen, I., Windhorst, A. D., Shalgunov, V. & Herth, M. M. The role of neuroimaging in Parkinson’s disease. J. Neurochem. 159, 660–689 (2021).34532856 10.1111/jnc.15516
26. Gu S Ye Q Yuan C Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson’s disease: a systematic review and meta-analysis Rev. Neurosci. 2019 30 743 756 10.1515/revneuro-2018-0061 31050657
Gu, S., Ye, Q. & Yuan, C. Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson’s disease: a systematic review and meta-analysis. Rev. Neurosci. 30, 743–756 (2019).31050657 10.1515/revneuro-2018-0061
27. Houssein NJ Henriksen AC Hejl A-M Marner L Diagnostic accuracy of cerebral [18F] FDG PET in atypical parkinsonism EJNMMI Res 2023 13 74 10.1186/s13550-023-01025-x 37572162
Houssein, N. J., Henriksen, A. C., Hejl, A.-M. & Marner, L. Diagnostic accuracy of cerebral [18F] FDG PET in atypical parkinsonism. EJNMMI Res 13, 74 (2023).37572162 10.1186/s13550-023-01025-x
28. Hu XH Multivariate radiomics models based on (18)F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy Eur. J. Nucl. Med. Mol. Imaging 2021 48 3469 3481 10.1007/s00259-021-05325-z 33829415
Hu, X. H. et al. Multivariate radiomics models based on (18)F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging 48, 3469–3481 (2021).33829415 10.1007/s00259-021-05325-z
29. Saeed, U., Lang, A. E. & Masellis, M. Neuroimaging Advances in Parkinson’s Disease and Atypical Parkinsonian Syndromes. Front. Neurol. 11, 572976 (2020).
30. Meles SK Teune LK Jong BMD Dierckx RA Leenders KL Metabolic Imaging in Parkinson Disease J. Nucl. Med. 2017 58 23 28 10.2967/jnumed.116.183152 27879372
Meles, S. K., Teune, L. K., Jong, B. M. D., Dierckx, R. A. & Leenders, K. L. Metabolic Imaging in Parkinson Disease. J. Nucl. Med. 58, 23–28 (2017).27879372 10.2967/jnumed.116.183152
31. Xiong M Qian Q Liang X Wei YD Serum levels of lipocalin-2 in patients with Parkinson’s disease Neurol. Sci. 2022 43 1755 1759 10.1007/s10072-021-05579-3 34455500
Xiong, M., Qian, Q., Liang, X. & Wei, Y. D. Serum levels of lipocalin-2 in patients with Parkinson’s disease. Neurol. Sci. 43, 1755–1759 (2022).34455500 10.1007/s10072-021-05579-3
32. Wenning GK The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy Mov. Disord. 2022 37 1131 1148 10.1002/mds.29005 35445419
Wenning, G. K. et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov. Disord. 37, 1131–1148 (2022).35445419 10.1002/mds.29005
33. Höglinger GU Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria Mov. Disord. 2017 32 853 864 10.1002/mds.26987 28467028
Höglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 32, 853–864 (2017).28467028 10.1002/mds.26987
34. Wang, L. J. et al. Chinese experts’ consensus of diagnosis and treatment of vascular parkinsonism. Chin. J. Neurol. 50, 326–331 (2017).
35. Yang YJ Preserved caudate function in young-onset patients with Parkinson’s disease: a dual-tracer PET imaging study Ther. Adv. Neurol. Disord. 2019 12 1756286419851400 10.1177/1756286419851400 31205495
Yang, Y. J. et al. Preserved caudate function in young-onset patients with Parkinson’s disease: a dual-tracer PET imaging study. Ther. Adv. Neurol. Disord. 12, 1756286419851400 (2019).31205495 10.1177/1756286419851400
36. Zhao Y Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning Eur. J. Nucl. Med. Mol. Imaging 2022 49 2798 2811 10.1007/s00259-022-05804-x 35588012
Zhao, Y. et al. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur. J. Nucl. Med. Mol. Imaging 49, 2798–2811 (2022).35588012 10.1007/s00259-022-05804-x
37. Huang ZM Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder J. Cereb. Blood Flow. Metab. 2020 40 552 562 10.1177/0271678X19828916 30741074
Huang, Z. M. et al. Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder. J. Cereb. Blood Flow. Metab. 40, 552–562 (2020).30741074 10.1177/0271678X19828916
38. Zhang T Nie B Liu H Shan B Alzheimer’s Disease Neuroimaging, I. Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas Eur. J. Nucl. Med. Mol. Imaging 2022 49 3073 3085 10.1007/s00259-022-05752-6 35258689
Zhang, T., Nie, B., Liu, H., Shan, B. & Alzheimer’s Disease Neuroimaging, I. Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas. Eur. J. Nucl. Med. Mol. Imaging 49, 3073–3085 (2022).35258689 10.1007/s00259-022-05752-6
39. Perju-Dumbrava LD Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy Mov. Disord. 2012 27 65 71 10.1002/mds.24000 22102521
Perju-Dumbrava, L. D. et al. Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov. Disord. 27, 65–71 (2012).22102521 10.1002/mds.24000
40. Black, J. A. et al. Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants. J. Neurol. Sci. 271, 4267–4280 (2024).
41. Lindstrom E Danfors T Lindsjo L Lubberink M Brain-PET image reconstruction methods affect software-aided diagnosis in patients with neurodegenerative diseases J. Nucl. Med. 2018 59 1780 30262519
Lindstrom, E., Danfors, T., Lindsjo, L. & Lubberink, M. Brain-PET image reconstruction methods affect software-aided diagnosis in patients with neurodegenerative diseases. J. Nucl. Med. 59, 1780 (2018).30262519
42. Lindström, E. et al. Image reconstruction methods affect software-aided assessment of pathologies of [18F] flutemetamol and [18F] FDG brain-PET examinations in patients with neurodegenerative diseases. Neuroimage Clin. 28, 102386 (2020).
